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In Brief
Han et al. examine the role of JNK in
inflammation-associated liver disease.
Myeloid cell JNK deficiency reduces the
expression of inflammatory cytokines
and chemokines, reduces hepatic
infiltration by inflammatory cells, and
suppresses the development of hepatitis
and hepatocellular carcinoma. JNK in
myeloid cells is therefore a key regulator
of hepatic inflammation.
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The cJun NH2-terminal kinase (JNK) signaling path-
way is required for the development of hepatitis and
hepatocellularcarcinoma.A role for JNK in liverparen-
chymal cells has been proposed, but more recent
studies have implicated non-parenchymal liver cells
as the relevant site of JNK signaling. Here, we tested
thehypothesis thatmyeloidcellsmediate this function
of JNK. We show that mice with myeloid cell-specific
JNK deficiency exhibit reduced hepatic inflammation
and suppression of both hepatitis and hepatocellular
carcinoma. These data identify myeloid cells as a
site of pro-inflammatory signaling by JNK that can
promote liver pathology. Targeting myeloid cells
with a drug that inhibits JNK may therefore provide
therapeutic benefit for the treatment of inflamma-
tion-related liver disease.INTRODUCTION
Hepatocellular carcinoma (HCC) is a major cause of human
cancer death (Fitzmorris et al., 2015; Mikhail et al., 2014). The
worldwide incidence of HCC has increased in recent years, but
the management of patients with HCC has not dramatically
changed. Primary treatment options for early-stage disease
include surgical resection and liver transplantation. Unresect-
able disease is treated with loco-regional therapies and/or
systemic chemotherapy and is associated with poor rates of sur-
vival. New treatment options for patients with HCC are therefore
critically important.
The development of HCC appears to require hepatocyte death
that triggers disease progression from hepatitis associated with
a number of liver insults, including steatosis, hepatotoxins, viral
infection, and autoimmune disease (Luedde et al., 2014). These
changes are associated with the development of inflammation,
fibrosis, and cirrhosis. Recent studies have demonstrated that
inflammation is a hallmark of liver disease that may represent a
cause of HCC development (Sun and Karin, 2013). This insight
suggests that targeting hepatic inflammation may provide thera-
peutic benefit for the treatment of HCC.This is an open access article under the CC BY-NInflammatory responses are frequently associated with
mitogen-activated protein (MAP) kinases, including the cJun
NH2-terminal kinase (JNK) signaling pathway that is activated
by inflammatory cytokines, endotoxin, and physical-chemical
stress (Davis, 2000). This signaling pathway is mediated by ubiq-
uitously expressed JNK isoforms that are encoded by theMapk8
and Mapk9 genes (also known as Jnk1 and Jnk2) (Gupta et al.,
1996). JNK inhibition therefore represents a potential mecha-
nism for decreasing hepatic inflammation and preventing hepa-
titis and HCC.
Studies using JNK-deficient mice have confirmed that JNK
plays a key role in the development of hepatitis and HCC. For
example, Mapk8/ and Mapk9/ mice were reported to be
resistant to hepatitis (Maeda et al., 2003), although subsequent
studies indicated that JNK1 may play a primary role in this
response (Kamata et al., 2005; Chang et al., 2006). Moreover,
Mapk8/mice are resistant to the development of HCC (Sakurai
et al., 2006; Hui et al., 2008). Together, these studies demon-
strate that JNK plays a key role in hepatitis and the development
of HCC in mice.
To test whether JNK in liver parenchymal cells (hepatocytes) is
required for hepatitis and HCC development, studies have been
performed using tissue-specific JNK knockout mice. These
studies demonstrated that JNK in parenchymal cells is not
required for the development of hepatitis or HCC (Das et al.,
2009, 2011). Nevertheless, JNK deficiency in both parenchymal
and non-parenchymal cells did protect against hepatitis and
HCC (Das et al., 2009, 2011). These data indicate that non-
parenchymal cells may represent the site of JNK function that
is required for the development of hepatitis and HCC. However,
the identity of the relevant non-parenchymal cell population is
unclear. These hepatic cells include stellate cells, endothelial
cells that form blood vessels and bile ducts, and other cells
that mediate innate and adaptive immune responses.
We considered it likely that myeloid cells may represent a site
of JNK function during the development of hepatitis and HCC
because of the association of inflammation with liver disease
(Shirabe et al., 2012; Sun and Karin, 2013) and the role of JNK
in the promotion of inflammation (Han et al., 2013). The purpose
of this study was to test this hypothesis. We report that mice with
myeloid cell-specific JNK deficiency are resistant to hepatitis
and the development of HCC. These data identify myeloid cells
as a key site of JNK function in inflammation-related liverCell Reports 15, 19–26, April 5, 2016 ª2016 The Authors 19
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Myeloid JNK Promotes Hepatic
Infiltration by Monocytes and Neutrophils
(A) Mice (ØWT and ØKO) were treated with PBS or
LPS/GalN (5.5 hr). Representative flow cytometry
data of hepatic leukocytes stained with antibodies
to CD11b and F4/80 (red, infiltrating monocytes;
blue, Kupffer cells) are presented (top). Repre-
sentative flow cytometry data of neutrophils
stained with antibodies to CD11b and Gr-1 (red)
within total hepatic leukocytes (middle) and blood
(bottom) are presented.
(B) The total number of hepatic leukocytes is pre-
sented (mean ± SEM; PBS ØWT, n = 3; PBS ØKO,
n = 4; LPS/GalN ØWT, n = 13; LPS/GalN ØKO,
n = 12). The number of total hepatic leukocytes,
infiltrating monocytes, and infiltrating neutrophils
is presented (mean ± SEM; PBS ØWT, n = 5; PBS
ØKO, n = 6; LPS/GalN ØWT, n = 11 [except neu-
trophils, n = 16]; LPS/GalN ØKO, n = 11 [except
neutrophils, n = 15]). The percentage of total blood
leukocytes corresponding to neutrophils is also
presented (mean ± SEM). PBS groups, n = 3; LPS/
GalN groups, n = 9). Statistically significant differ-
ences between ØWT and ØKO mice are indicated
(***p < 0.001).
See also Figure S1.disease. This information is important for the design of potential
therapies based on the use of small molecules that target JNK
because the relevant cell population is now established (myeloid
cells). Moreover, relevant biomarkers for dose-ranging studies
(myeloid inflammatory molecules) can be defined. Together
with previous studies, this analysis confirms JNK inhibition as a
possible therapeutic strategy for the treatment of inflamma-
tion-related liver disease.
RESULTS
Mice with JNK Deficiency in Myeloid Cells
We established mice with myeloid cell-specific ablation of
the Mapk8 plus Mapk9 genes (LysM-cre+ Mapk8LoxP/LoxP
Mapk9LoxP/LoxP mice) and control mice (LysM-cre+). To test for20 Cell Reports 15, 19–26, April 5, 2016Mapk8 andMapk9 gene ablation, we iso-
lated Kupffer cells, macrophages, and
neutrophils from control (ØWT) and JNK-
deficient (ØKO) mice. Genotype analysis
demonstrated ablation of the Mapk8 and
Mapk9 genes in each cell population (Fig-
ure S1A). Immunoblot analysis confirmed
similar JNK expression in non-myeloid
cells of ØWT and ØKO mice, including
B cells, T cells, and hepatocytes (Fig-
ure S1A). Immunophenotyping demon-
strated that similar numbers of CD45+
leukocytes, dendritic cells (DCs), B cells,
T cells, natural killer T (NKT) cells, natural
killer (NK) cells, and monocytes in the
blood of ØWT and ØKO mice (Figure S1B).
Small changes in the number of B cells,T cells, and NK cells were detected in bone marrow and lymph
nodes, but no significant differences in these cell populations
were observed in the spleen or liver (Figure S1B). This analysis
demonstrates that myeloid cell JNK deficiency does not cause
major changes in leukocyte cell numbers. We conclude that
ØKO mice represent a model for studies of JNK deficiency in
myeloid cells (Han et al., 2013).
JNK Promotes Infiltration of the Liver by Inflammatory
Cells
We examined the hepatotoxic response of ØWT and ØKO mice
exposed to lipopolysaccharide (LPS) plus N-acetyl-galactos-
amine (GalN). Treatment with LPS/GalN caused a marked in-
crease in the total number of hepatic leukocytes in ØWT mice
(Figure 1). This increase in hepatic leukocytes was strongly
Figure 2. Myeloid JNK Deficiency Sup-
presses Expression of Inflammatory Cyto-
kines
(A) Hepatic expression of the chemokine receptors
(Ccr2, Ccr4, Ccr5, Cxcr1, and Cxcr2), ligands
(Ccl2, Ccl3, Ccl4, Ccl5, Ccl7, Ccl8, Ccl17, Ccl22,
Cxcl1, Cxcl2, and Cxcl5), and inflammatory cyto-
kines (Il1b, Il6, and Tnfa) is presented. The data
show relative mRNA expression (mean ± SEM;
n = 8) measured by qRT-PCR assays using total
RNA isolated fromØWT and ØKOmice treated (6 hr)
with PBS or LPS/GalN.
Statistically significant differences between ØWT
and ØKO mice are indicated (*p < 0.05; **p < 0.01;
***p < 0.001).
(B) The concentration of inflammatory cytokines
and chemokines in the blood of ØWT and ØKO mice
treated with LPS/GalN was measured by multi-
plexed ELISA (mean ± SEM; n = 10). Statistically
significant differences between ØWT and ØKOmice
are indicated (*p < 0.05; **p < 0.01).
(C) The expression of TNF-a by hepatic myeloid
cells (infiltrating monocytes, Kupffer cells, and
neutrophils) was measured by intracellular stain-
ing. The percentage TNF-a-positive cells was
quantified (mean ± SEM; PBS, n = 3; LPS/GalN,
n = 6). Statistically significant differences between
ØWT and ØKO mice are indicated (*p < 0.05).
See also Figure S2.suppressed (p < 0.001) in LPS/GalN-treated ØKOmice (Figure 1).
Flow cytometry using CD11b and F4/80 antibodies identified
populations of Kupffer cells (CD11blow F4/80hi) and infiltrating
monocytes (CD11bhi F4/80low) (Movita et al., 2012). No signifi-
cant change in the Kupffer cell population was detected (Fig-
ure 1). In contrast, the infiltrating monocyte population was
increased in LPS/GalN-treated ØWT mice, and this increase
was suppressed (p < 0.001) in ØKO mice (Figure 1).
We also examined neutrophils in the ØWT and ØKO mice. Flow
cytometry demonstrated that treatment with LPS/GalN caused a
similar increase in the number of neutrophils (Gr-1hi Cd11b+)
circulating in the blood of ØWT andØKOmice (Figure 1). However,the increased hepatic neutrophil popula-
tion in LPS/GalN-treated ØWT mice was
suppressed in ØKO mice (p < 0.001) (Fig-
ure 1). Together, these data indicate that
while JNK deficiency does not alter the
LPS/GalN-stimulatedmobilization of neu-
trophils from the bone marrow, JNK defi-
ciency does suppress the infiltration of
neutrophils into the liver.
The JNK-mediated promotion of he-
patic infiltration by monocytes and neu-
trophils (Figure 1) may be caused by
chemokines (Marra and Tacke, 2014).
We therefore examined whether myeloid
cell JNK deficiency disrupted chemo-
kine-signaling networks. The monocyte
chemokine receptor CCR2 binds ligands
(CCL2, CCL7, and CCL8) that are ex-pressed at low levels in the liver of LPS/GalN-treated ØKO mice
comparedwith LPS/GalN-treatedØWTmice (Figure 2A). A similar
reduction in expression of ligands CCL3, CCL4, CCL5, and
CCL8 that bind the chemokine receptor CCR5 (Figure 2A); the li-
gands CCL2, CCL4, CCL5, CCL17, and CCL22 that bind the
chemokine receptor CCR4; and the ligands CXCL1, CXCL2,
and CXCL5 that bind the chemokine receptors CXCR1 and
CXCR2 (Figure 2A) were detected in the liver of LPS/GalN-
treated ØKO mice compared with LPS/GalN-treated ØWT mice.
These changes in chemokine signaling may contribute to
reduced hepatic infiltration by inflammatory cells detected in
ØKO mice compared with ØWT mice.Cell Reports 15, 19–26, April 5, 2016 21
Figure 3. Myeloid JNK Deficiency Sup-
presses the Development of Fulminant
Hepatitis
(A) Mice (ØWT and ØKO) were treated with PBS or
LPS/GalN (6 hr). Representative images of the
dissected liver (scale bar represents 5 mm) and
H&E-stained liver sections are presented (top).
Apoptotic cells in the liver sections were examined
by TUNEL assay (bottom). Scale bars represent
100 mm.
(B) The accumulation of hepatic aminotransfer-
ases (ALT and AST) in the blood of ØWT and ØKO
mice was measured (mean ± SEM; n = 10, except
ALT at 6 hr, n = 9). Statistically significant differ-
ences between LPS/GalN-treated ØWT and ØKO
mice are indicated (**p < 0.01).
(C) Liver extracts prepared from mice treated with
PBS or LPS/GalN (6 hr) were examined by immu-
noblot analysis using antibodies to a-tubulin,
Bad, caspase-3, cleaved caspase-3, PARP, and
cleaved PARP.
(D) Kaplan-Meier analysis of survival following
treatment of ØWT and ØKO mice with LPS/GalN
(n = 15).
See also Figure S3.JNK Promotes the Expression of Inflammatory
Cytokines
The requirement of JNK for normal myeloid cell infiltration of
the liver following treatment of mice with LPS/GalN (Figure 1)
suggests that JNK plays an important role in the promotion
of hepatic inflammation. To explore the role of JNK in
inflammation, we examined the hepatic expression of inflam-
matory cytokines in mice treated with LPS/GalN. We found
reduced amounts of inflammatory cytokines (interferon g
[IFN-g], interleukin-1b [IL-1b], IL-6, and tumor necrosis
factor a [TNF-a]) and chemokines (CCL2 and CCL5) circulating
in the blood of LPS/GalN-treated ØKO mice compared with ØWT
mice (Figure 2B). This reduction in cytokine and chemokine
expression is consistent with the reduced expression of che-
mokine mRNA (Figure 2A) and inflammatory cytokine mRNA
(Figure 2A) detected in the liver of ØKO mice compared with
ØWT mice.
Myeloid cells represent a source of inflammatory cytokines
(e.g., TNF-a) in mice treated with LPS/GalN. We therefore per-
formed intracellular staining to detect the expression of TNF-a
by hepatic leukocytes. We found that JNK deficiency caused
significantly reduced TNF-a expression (p < 0.05) by Kupffer
cells, infiltrating monocytes, and neutrophils (Figures 2C and
S2). Together, these data demonstrate that multiple myeloid
cell types may contribute to the suppression of TNF-a expres-
sion caused by JNK deficiency.22 Cell Reports 15, 19–26, April 5, 2016JNK Promotes the Development
Fulminant Hepatitis
The reduction of hepatic infiltration by
myeloid cells (Figure 1) and the decreased
expression of inflammatory cytokines
(Figure 2) suggest that LPS/GalN-induced
hepatitis may be suppressed in ØKO micecomparedwithØWTmice. Indeed,we found thatmyeloid cell JNK
deficiency caused reduced hepatic hemorrhage and reduced
TUNEL staining of apoptotic cells (Figure 3A). We also examined
serum aminotransferases (a marker for hepatic damage) in LPS/
GalN-treatedØWTandØKOmice. This analysis demonstrated that
JNK deficiency significantly (p < 0.01) reduced the amount of
serumalanine aminotransferase (ALT) and aspartate aminotrans-
ferase (AST) in ØKO mice compared with ØWT mice (Figure 3B).
Immunoblot analysis of liver extracts demonstrated reduced
expression of Bad, a pro-apoptotic BH3-only protein implicated
in LPS/GalN-induced hepatitis (Takamura et al., 2007), in liver ex-
tracts prepared from in LPS/GalN-treated ØWT and ØKO mice.
Moreover, we found reduced caspase-3 activation and reduced
cleavage of PARP (a caspase-3 substrate) inØKOmice compared
with ØWT mice (Figure 3C). Consistent with these observations,
the survival of ØKO mice was significantly increased (p < 0.005)
comparedwithØWTmice following treatmentwith LPS/GalN (Fig-
ure 3D). Together, these data demonstrate that JNK in myeloid
cells can function to promote the development of fulminant
hepatitis.
It is established that the LPS/GalN model of hepatitis depends
upon the interaction of soluble TNF-awith TNF-R1 (Nowak et al.,
2000). Our analysis suggests that reduced TNF-a expression
(Figure 2) may account for the resistance of ØKO mice to LPS/
GalN-induced hepatitis compared with ØWT mice. However, it
is also possible that ØKOmice exhibit a defect in TNF-a signaling.
To test this hypothesis, we compared the response of ØWT and
ØKO mice to treatment with TNF-a/GalN. We found that TNF-a/
GalN caused similar hepatic hemorrhage (Figure S3A) and
similar concentrations of serum aminotransferases (ALT and
AST) in ØWT and ØKO mice (Figure S3B). Moreover, biochemical
analysis of liver extracts demonstrated similar caspase-3 activa-
tion and PARP cleavage in ØWT and ØKO mice (Figure S3C). No
significant difference in the blood concentration of inflammatory
cytokines (IL-6 and TNF-a) or chemokines (CCL2 and CCL5) be-
tween ØWT and ØKO mice was detected (Figure S3D). Flow cy-
tometry demonstrated that TNF-a/GalN caused similar hepatic
infiltration by inflammatory cells in ØWT and ØKO mice (Fig-
ure S3E). Together, these data demonstrate that JNK-deficiency
in myeloid cells suppresses TNF-a expression (Figure 2), but
does not suppress TNF-a signaling (Figure S3) in a mouse model
of hepatitis, including increased hepatic infiltration by myeloid
cells (Figure S3E).
JNK in Myeloid Cells Promotes the Development of HCC
It is established that the development of HCC is increased by
inflammation (Sun and Karin, 2013). Since hepatic inflammation
is suppressed in ØKO mice compared with ØWT mice (Figures 1,
2, and 3), we anticipated that JNK deficiency in myeloid cells
might protect mice against the development of HCC. To test
this hypothesis, we examined the development of HCC in ØWT
and ØKO mice using the diethylnitrosamine (DEN) model of liver
cancer. The mice were exposed to the carcinogen DEN at age
2weeks, and tumor development was examined at age 38weeks
(Figure 4A). JNK deficiency in myeloid cells caused significantly
decreased liver mass (p < 0.05) and decreased tumor size
(p < 0.01), but it did not cause a significant change in the number
of hepatic tumors detected by macroscopic examination (Fig-
ure 4B). Examination of liver sections by a pathologist demon-
strated that myeloid cell JNK deficiency decreased the
development of adenoma and carcinoma (Figure S4A). Control
studies indicated that HCC in ØWT and ØKO mice expressed
similar amounts of JNK (Figure S4B). Together, these data
demonstrate that JNK in myeloid cells is not required for
tumor formation, but myeloid cell JNK acts to promote tumor
development by increasing both tumor grade and tumor mass.
To test this conclusion, we examined a different model of
hepatic tumor development. We found that liver tumors
caused by intrasplenic injection of B16 melanoma cells were
markedly suppressed inØKOmice comparedwith ØWTmice (Fig-
ures S4C and S4D). This observation confirms the conclusion
that JNK in myeloid cells can promote tumor development in
the liver.
Liver sections stained by TUNEL assay and an antibody to the
proliferation marker PCNA demonstrated that myeloid cell JNK
deficiency caused both decreased hepatocyte cell death and
decreased proliferation in the DEN model of HCC (Figure 4C).
This observation is consistent with a role for JNK-mediated
inflammation in damage-induced regeneration during develop-
ment of HCC (Das et al., 2011). To test whether JNK in myeloid
cells contributes to tumor-associated inflammation, we exam-
ined the expression of cytokines and chemokines. Blood anal-
ysis demonstrated decreased amounts of chemokines and
inflammatory cytokines (Figure 4D). It is likely that the observedreduction in cytokine and chemokine expression reflects both
expression by myeloid cells and also actions of myeloid cells
on expression by different cell types, including other immune
cells and tumor cells. Indeed, we found decreased hepatic
expression of markers of CD8 T cells (but not CD4 T cells), reg-
ulatory T cells (Tregs; Foxp3), and macrophages (Emr1; F4/80)
(Figure 4E) together with inflammatory cytokine mRNA (Il1b,
Il6, and Tnfa) and chemokines/chemokine receptor mRNA,
including Ccr2 (and ligands Ccl2, Ccl7, and Ccl8), Ccr4 (and li-
gands Ccl2, Ccl4, Ccl5, Ccl17, and Ccl22), Ccr5 (and ligands
Ccl3, Ccl4, Ccl5, and Ccl8), and Cxcr1/2 (and ligands Cxcl1,
Cxcl2, andCxcl5) in ØKO tumors comparedwithØWT tumors (Fig-
ure 4F). These data confirm that JNK in myeloid cells promotes
tumor-associated inflammation.
Studies of cell-cycle regulatory gene expression demon-
strated that myeloid cell JNK deficiency caused decreased tu-
mor-associated expression of Cdk1, cMyc, p15INK4B, p21CIP1,
and Tgfb1 mRNA (Figure 4F). The finding that ØKO tumors
express decreased amounts of Cdk1 and cMyc compared
with ØWT tumors is consistent with the larger tumor burden
of control mice in comparison to myeloid cell JNK-deficient
mice.
DISCUSSION
It is established that immunosurveillance plays a key role in tu-
mor development (Hanahan and Weinberg, 2011) that can lead
to either prevention or promotion of cancer (Schreiber et al.,
2011). Pro-tumorigenic inflammation is generally associated
with tumor infiltration by M2-like macrophages, myeloid-derived
suppressor cells, Th2 cells, and Treg cells (Melief and Finn,
2011). In contrast, anti-tumorigenic inflammation is most often
associated with tumor infiltration by M1-like macrophages, Th1
cells, and CD8+ cytotoxic T cells (Melief and Finn, 2011). The bal-
ance of these inflammatory mechanisms represents one factor
that controls tumor formation.
Interestingly, bothM1-like andM2-likemacrophages (and also
mixed-phenotypemacrophages) are present in tumors, although
there appears to be regional localization with M1-like macro-
phages primarily located in the peri-tumoral stroma and M2-
like macrophages within the growing tumor (Kuang et al.,
2007). Tumor development is associated with the progressive
replacement of M1-like macrophages during early stages by
M2-like macrophages within established tumors (Capece et al.,
2013). The mechanism of macrophage polarization to the M2
phenotype in tumors may involve multiple mechanisms,
including IL4 produced by T cells (DeNardo et al., 2009) and lac-
tic acid produced by tumor cells (Colegio et al., 2014), that regu-
late signaling pathways that control macrophage polarization
(Zhou et al., 2014).
The JNK signaling pathway is implicated in the control of
macrophage polarization (Zhou et al., 2014). Consequently,
reduced JNK signaling causes decreased expression of the
M1-associated pro-inflammatory cytokines TNF-a, IL-1b, and
IL-6 (Han et al., 2013) and reduced expression of the M2-asso-
ciated chemokines CCL17 and CCL22 (Hefetz-Sela et al.,
2014). These observations are significant because TNF-a,
IL-1b, and IL-6 promote hepatic inflammation, hepatitis, andCell Reports 15, 19–26, April 5, 2016 23
Figure 4. Myeloid JNK Promotes the Devel-
opment of HCC
(A) Mice (ØWT and ØKO) were treated with dieth-
ylnitrosamine (DEN) at age 2 weeks and eutha-
nized at age 38 weeks. Representative images
of livers (scale bar represents 5 mm) and H&E-
stained liver sections (scale bar represents
100 mm) are presented.
(B) The total body mass, liver mass, surface tumor
number, and tumor size are presented (mean ±
SEM). Body mass: ØWT, n = 17; ØKO, n = 14. Liver
mass: ØWT, n = 18; ØKO, n = 14. Tumor number and
size: ØWT, n = 19; ØKO, n = 14. Statistically signif-
icant differences between ØWT and ØKO mice are
indicated (*p < 0.05; **p < 0.01).
(C) Representative sections of liver stained with
DAPI (blue) and by TUNEL assay (green) or with an
antibody to PCNA (green) are presented. Scale bar
represents 100 mm.
(D) The concentration of blood cytokines (IL-1b,
IL-6, and TNF-a) and chemokines (CCL2 and
CCL5) was measured by multiplexed ELISA
(mean ± SEM). ØWT, n = 21; ØKO, n = 13). Statis-
tically significant differences between ØWT and
ØKO mice are indicated (*p < 0.05; **p < 0.01).
(E) Hepatic mRNA associated with immune cell
subsets (Cd4, Cd8, Foxp3, and Emr1 [F4/80]) was
examinedbyqRT-PCRassays (mean±SEM; n = 3).
Statistically significant differences between ØWT
and ØKO mice are indicated (*p < 0.05; **p < 0.01).
(F) The expression of hepatic mRNA for inflam-
matory cytokines (Il1a, Il1b, Il6, and Tnfa) and the
cytokine target gene Socs3, chemokine receptors
(Ccr2, Ccr4, Ccr5, Cxcr1, and Cxcr2), chemokine
ligands (Ccl2, Ccl3, Ccl4, Ccl5, Ccl7, Ccl8, Ccl17,
Ccl22, Cxcl1, Cxcl2, and Cxcl5), and proliferation-
associated genes (Cdk1, p15INK4B, p21CIP1, cMyc
and Tgfb1) are presented as a heatmap of log2-
transformed data normalized to control ØWT mice
(mean; n = 3).
See also Figure S4.HCC development (Park et al., 2010; Negash and Gale, 2015)
and CCL17/CCL22 can act as chemoattractants for tumor-
associated Foxp3+ Tregs that regulate anti-tumor immunity
(Nishikawa and Sakaguchi, 2010). Consequently, decreased
expression of chemokines and inflammatory cytokines by
JNK-deficient myeloid cells may contribute to reduced hepatic
infiltration by inflammatory cells and the suppression of both
hepatitis and HCC detected in ØKO mice compared with ØWT
mice (Figures 3 and 4). Moreover, JNK in myeloid cells may in-
fluence the overall inflammatory microenvironment through
immunoregulatory cells (Figure 4E), including CD8+ Foxp3+
Tregs that are associated with high-grade HCC development
(Yang et al., 2010).24 Cell Reports 15, 19–26, April 5, 2016In conclusion, we identify myeloid cells
as a site of pro-inflammatory signaling by
the JNK-signaling pathway that can pro-
mote liver pathology. Targeting myeloid
cells with a drug that inhibits JNK may
therefore provide therapeutic benefit forthe treatment of inflammation-related liver disease. A challenge
for the design of such therapy is the potential for altered innate
and adaptive immune responses caused by defects in macro-
phage function.
EXPERIMENTAL PROCEDURES
Mice
C57BL/6J mice (stock no. 000664) and B6.129P2-Lyz2tm1(cre)Ifo/J mice (stock
no. 004781) (Clausen et al., 1999) were obtained from The Jackson Laboratory.
We have previously described Mapk8LoxP/LoxP mice (Das et al., 2007) and
Mapk9 LoxP/LoxP mice (Han et al., 2013). The mice were backcrossed to the
C57BL/6J strain (ten generations) and housed in a specific-pathogen-free
facility (accredited by the American Association for Laboratory Animal Care)
at 20C using laminar flow cages. The Institutional Animal Care and Use Com-
mittee of the University of Massachusetts Medical School approved all studies
using animals.
Hepatitis was induced by intraperitoneal (i.p.) injection (male mice at age
8–10 weeks) with 35 mg/kg E. coli 0111:B LPS (Sigma-Aldrich) plus
750 mg/kg GalN (Sigma-Aldrich) or 20 mg/kg TNF-a (R&D Systems) plus
750 mg/kg GalN (Galanos et al., 1979; Wallach et al., 1988). Kaplan-Meier
analysis was performed using mice treated with 25 mg/kg LPS plus
750 mg/kg GalN. Carcinogen-induced HCC was induced by i.p. injection
(male mice at age 2 weeks) with a single dose (25 mg/kg) of DEN (Sigma)
diluted in glyceryl trioctanoate (Sigma); the mice were euthanized at
age 38 weeks. Control mice were injected with solvent alone. Liver metastasis
was examined usingmice (6–7 weeks old) intrasplenically injected with 13 106
B16 melanoma cells in 100 ml PBS (Kitajima et al., 2008); the mice were eutha-
nized on day 12 post-injection.
Statistical Analysis
Data are expressed as the mean ± SEM to assess whether the variance of
each group was similar. The statistical significance of differences between
groups was examined using Student’s test (two-sided) or ANOVA with the
Fisher’s test. Kaplan-Meier analysis was performed using the log-rank test.
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